KathleenARickardMD

Pulmonology • Chapel Hill, NC

Critical Care Medicine

Physician

Join to view full profile

Dr. Rickard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rickard's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 919-966-4996

Fax+1 919-843-5515

Education & Training

University of Nebraska Medical Center College of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989
Ohio State University HospitalResidency, Internal Medicine, 1983 - 1986
Drexel University College of MedicineClass of 1983

Certifications & Licensure

NC State Medical License 1994 - 2019
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

12 citations
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
Gary T. Ferguson, Edward Kerwin, Tara Rheault, Thomas Bengtsson, Kathleen Rickard
International Journal of Chronic Obstructive Pulmonary Disease. 2021-04-22
8 citations
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed An...
Henrik Watz, Kathleen Rickard, Tara Renae Rheault, Thomas Bengtsson, Dave Singh
International Journal of Chronic Obstructive Pulmonary Disease. 2020-09-16
2 citations
Measurement of FeNO with a portable, electrochemical analyzer using a 6-second exhalation time in 7-10-year-old children with asthma: comparison to a 10-second exhalat...
Kathleen A. Rickard, Neal Jain, Margot MacDonald-Berko
The Journal of Asthma. 2019-12-01

Press Mentions

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019October 15th, 2019
Verona Pharma Strengthens Its Clinical Team Ahead of Phase 3 Development of EnsifentrineJune 24th, 2019
Verona Pharma plc:Operational Update and Financial Results for the Three and Six Months Ended June30, 2019March 31st, 2019
Join now to see all